Loading clinical trials...

Pharmacogenetic Prediction of Metoprolol Effectiveness | Clinical Trials | Clareo Health

TERMINATEDNA

Pharmacogenetic Prediction of Metoprolol Effectiveness

NCT02293096•University of Colorado, Denver

Summary

The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial. The investigators will determine each individual's genotype for both CYP2D6 and Adrenoceptor Beta 1 (ADRB1). Metabolomic markers will be identified to determine if specific metabolites are associated with drug response. The investigators' overall objective is to determine if genetics predicts metoprolol succinate response better than clinical factors such as age, race, body mass index, dose, and medication co-ingestion.

Eligibility

Age

30 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subjects between age \>30 years and \< 80 years
•2. Subjects have diagnosis of uncontrolled essential hypertension.

Exclusion Criteria

•1. end stage liver disease,
•2. end stage renal disease,
•3. pregnant females,
•4. American Society of Anesthesiologists (ASA) classification of \>3,
•5. wards of the state, prisoners,
•6. decisionally challenged,
•7. HR\<60 bpm,
•8. AV block\>240 msec,
•9. active reactive airway disease,
•10. illicit drug abuse in the preceding 30 days,
+3 more criteria

Locations (1)

University of Colorado Denver; Emergency Department

Aurora, Colorado, United States

Key Dates

Start Date

September 1, 2014

Primary Completion Date

August 23, 2017

Completion Date

August 23, 2017

Last Updated

September 16, 2021

Enrollment

462

ACTUAL participants

Conditions

Hypertension

Interventions

metoprolol succinate

DRUG

Genotyping

GENETIC

CYP2D6 Phenotyping

PROCEDURE

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacogenetic Prediction of Metoprolol Effectiveness

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets